abbrevi
sever
acut
respiratori
syndrom
sar
coronaviru
cov
receptor
bind
domain
rbd
angiotensin
convert
enzym
fragment
antigen
bind
fab
word
health
organizz
complementarydetermin
region
cdr
swisspdbview
spdbv
abstract
recent
sever
acut
respiratori
syndrom
known
corona
viru
diseas
spread
much
rapidli
sever
induc
world
health
organ
declar
state
emerg
new
coronaviru
pandem
sever
countri
chosen
almost
complet
lockdown
slow
spread
scientif
commun
call
respond
devast
outbreak
identifi
new
tool
diagnosi
treatment
danger
aim
perform
silico
compar
model
analysi
allow
gain
new
insight
main
conform
chang
occur
spike
protein
level
receptor
bind
domain
rbd
along
interact
human
cell
angiotensin
convert
enzym
receptor
favour
human
cell
invas
furthermor
analysi
provid
ideal
pipelin
identifi
alreadi
character
antibodi
might
target
spike
rbd
prevent
interact
human
ii
instruct
build
new
possibl
neutral
antibodi
accord
chemicalphys
space
restraint
complementari
determin
region
cdr
mutagenesi
identifi
exist
antibodi
propos
antibodi
show
silico
high
affin
spike
rbd
use
refer
antibodi
also
build
new
high
affin
antibodi
present
futur
coronaviru
abl
invad
human
cell
interact
spike
protein
human
gener
analysi
provid
indic
setup
right
biolog
molecular
context
investig
spike
interact
develop
new
vaccin
diagnosi
kit
treatment
base
usag
target
spike
protein
authorfund
right
reserv
reus
allow
without
permiss
scientif
commun
call
respond
pandem
respiratori
diseas
spread
impress
rate
among
peopl
world
new
coronaviru
call
relat
diseas
indic
report
posit
patient
world
april
th
ascertain
die
peopl
due
complic
also
appear
number
might
smaller
number
real
case
due
inabl
quantifi
rescu
asymptomat
peopl
order
limit
death
rate
spread
need
develop
vaccin
identifi
new
small
molecul
abl
prevent
treat
complic
well
prepar
new
quick
diagnosi
kit
abl
quantifi
real
number
peopl
expos
among
main
actor
infect
spike
protein
rna
depend
rna
polymeras
proteas
deserv
mention
inde
rna
depend
rna
polymeras
becom
one
main
target
nucleosid
analog
antivir
drug
remdesivir
alreadi
use
reduc
complic
due
ebola
dengu
merscov
infect
time
viral
proteas
inhibitor
investig
abil
prevent
viru
protein
specif
refer
spike
protein
cleavag
lead
fusion
viru
protein
host
cell
membran
also
antiinflammatori
antibodiesdrug
combin
anticoagul
molecul
investig
limit
coagulopathi
cytokin
signal
impress
trigger
infect
final
spike
protein
becom
investig
target
due
abil
form
interact
human
receptor
caus
fusion
event
make
possibl
viru
penetr
host
human
cell
crucial
role
play
spike
protein
also
due
possibl
use
recombin
spike
protein
trigger
immun
respons
work
vaccin
may
help
prevent
treat
covid
similarli
propos
recent
clarifi
infect
mechan
sever
research
group
recent
solv
crystal
structur
entir
spike
protein
prefus
conform
andor
spike
rbd
domain
complex
human
light
avail
cite
crystallizedcryoem
solv
structur
propos
strategi
identifyingdraw
new
antibodi
direct
rbd
could
use
contrast
infect
aim
prevent
prepostfus
spike
conform
interconvers
respons
viru
invas
provid
molecular
structur
context
studi
new
diagnosi
kit
base
interact
engin
antibodi
human
spike
rbd
covspik
homologu
proteincrystal
structur
search
use
fold
recognit
method
implement
pgenthread
itass
accord
valid
protocol
sequenc
retriev
crystal
structur
refer
crystal
structur
indic
certain
high
confid
level
pgenthread
output
align
use
clustalw
implement
jalview
packag
coordin
crystal
structur
superimpos
compar
purpos
use
pymol
accord
compar
model
spike
trimer
postfus
conform
built
multitempl
model
use
model
detail
human
spike
protein
sequenc
align
sequenc
avail
entir
post
fusion
conform
murin
coronaviru
spike
protein
remain
avail
crystal
subdomain
coronaviru
spike
protein
post
fusion
conform
sequenc
cite
crystal
structur
fragment
use
queri
sequenc
sampl
correspond
entir
spike
monom
sequenc
reciprocalblastp
align
sequenc
investig
structur
compar
purpos
obtain
msa
use
drive
multitempl
model
complex
model
repres
prefus
spike
trimer
interact
three
function
receptor
unit
built
superimpos
recent
solv
cryoem
prefus
structur
spike
trimer
complex
spike
rbd
crystal
complex
human
spike
trimer
interact
one
function
receptor
conform
spikerbd
crystal
complex
human
investig
prepostfus
conform
interconvers
superimpos
prefus
avail
crystal
structur
spike
protein
gener
model
prefus
conform
spike
trimer
complex
three
unit
obtain
model
post
fusion
conform
gener
atom
model
energet
minim
use
yasara
minim
server
start
atom
coordin
crystal
neutral
antibodi
direct
spike
rbd
domain
model
interact
spike
rbd
domain
superimpos
fragment
antigen
base
fab
portion
complex
rbd
spike
rbd
domain
complex
use
pymol
creat
specif
antibodi
direct
spike
rbd
replac
residu
cdr
region
crystal
fab
portion
residu
may
complement
fulfil
better
rbd
surfac
mutagenesi
analys
model
incomplet
residu
within
crystal
structur
perform
use
spdbv
andor
pymol
propos
complet
igg
chimer
antibodi
obtain
superimpos
cite
result
engin
fab
portion
complex
rbd
atom
model
crystal
igg
avail
pdb
use
spdbv
pymol
accord
valid
protocol
allow
model
miss
residu
solv
clash
break
backbon
glycosyl
ladder
come
crystal
structur
investig
altern
retain
within
gener
structur
model
superimposit
oper
allow
backbon
connect
renumb
atom
residu
present
result
final
pdb
file
use
inhous
develop
perl
script
obtain
final
model
examin
vmd
pymol
spdbv
accord
protocol
gener
atom
model
energet
minim
use
yasara
minim
server
foldx
analysecomplex
assay
perform
determin
interact
energi
four
gener
antibodi
rbd
domain
spike
protein
also
determin
interact
energi
interact
spike
rbd
compar
purpos
way
foldx
analysecomplex
oper
unfold
select
target
determin
stabil
remain
molecul
subtract
sum
individu
energi
global
energi
neg
energi
indic
better
bind
posit
energi
indic
bind
energi
calcul
crystal
rbd
protein
complex
use
refer
valu
main
event
allow
viru
envelop
fusion
host
human
cell
plasma
membran
concern
conform
chang
occur
spike
protein
convert
prefus
conform
postfus
conform
interact
spike
protein
cleavag
spike
protein
trimer
resolv
cryoem
postfus
conform
avail
yet
accord
coutard
et
al
protein
cleavag
site
produc
divis
spike
protein
two
subdomain
ie
nter
si
ectodomain
contain
rbd
interact
cter
sii
membran
anchor
subdomain
form
spike
protein
post
fusion
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
conform
abl
trigger
fusion
viral
envelop
host
cell
plasma
membran
determin
host
cell
invas
provid
msa
fig
possibl
observ
conserv
cleavag
site
accord
sequenc
ctermin
domain
result
cleavag
start
cite
multitempl
sequenc
align
accord
valid
protocol
multitempl
model
built
model
monom
spike
protein
post
fusion
conform
fig
model
spike
postfus
conform
consist
residu
residu
number
result
protein
cleavag
also
protein
fragment
solv
structur
align
aminoacid
residu
number
counterpart
trimer
spike
protein
post
fusion
conform
obtain
duplic
two
time
obtain
monom
superimpos
three
spike
protein
monom
three
spike
protein
monom
report
fig
compar
model
spike
protein
trimer
built
multitempl
compar
model
show
rmsd
lower
murin
coronaviru
spike
protein
postfus
conform
result
model
fig
appear
elong
narrow
accord
observ
fragment
spike
protein
crystal
postfus
conform
whose
sequenc
report
fig
whose
pdbid
list
supp
tab
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
model
main
interact
occur
spike
protein
thank
high
percentag
ident
residu
share
spike
rbd
sever
cov
strain
fig
possibl
structur
align
three
object
consist
human
spikerbd
protein
complex
human
spikerbd
protein
complex
spike
protein
trimer
detail
superimposit
perform
use
pymol
lead
structur
align
rbd
spike
protein
fig
follow
structur
align
spike
protein
trimer
notabl
obtain
effici
superimposit
two
rbd
domain
rmsd
lower
human
spike
protein
also
due
high
percentag
ident
residu
possibl
superimpos
crystal
spike
protein
prefus
conform
model
spike
protein
trimer
postfus
conform
show
deep
conform
chang
occur
along
conform
interconvers
fig
appar
postfus
conform
appear
elong
narrow
prefus
conform
top
portion
postfus
conform
locat
beyond
receptor
fig
known
anchor
plasma
membran
involv
intern
event
avail
crystal
structur
obtain
structur
model
possibl
highlight
spike
rbd
spike
rbd
residu
involv
bind
human
fig
supp
tab
notabl
ion
pair
interact
observ
spike
rbd
human
also
observ
spike
rbd
human
report
data
repres
updatedintegr
analysi
similar
one
report
light
recent
deposit
spike
rbd
complex
human
tab
list
rbd
residu
bold
black
residu
delimit
border
indic
pair
cluster
residu
involv
polar
interprotein
interact
normal
black
residu
indic
residu
protein
interfac
distant
less
longest
chain
chosen
within
crystal
structur
multipl
chain
highlight
list
interact
residu
rbd
crystal
complex
fab
domain
two
differ
antibodi
name
show
high
affin
spike
rbd
abl
block
attach
nevertheless
show
differ
peculiar
mechan
action
inde
bind
rbd
similarli
abl
trigger
sarscov
spike
transit
postfus
conform
clarifi
yet
viruscel
fusion
may
trigger
also
interact
occur
close
surfac
cell
target
varianc
antibodi
appear
abl
prevent
interact
spike
prepostfus
conform
transit
neutral
viru
attack
thank
high
percentag
ident
residu
spike
rbd
domain
highli
similar
tertiari
structur
observ
rmsd
coordin
rbd
spike
protein
possibl
evalu
interact
spike
rbd
propos
sequencestructur
ideal
fab
chimer
antibodi
target
spike
rbd
domain
prevent
fusion
event
thu
follow
infect
aim
firstli
highlight
differ
rbd
portion
bound
known
antibodi
superimpos
rbd
rbd
highlight
differ
residu
involv
direct
interact
cdr
region
cdr
region
fig
tab
authorfund
right
reserv
reus
allow
without
permiss
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
due
uncertain
data
concern
fusion
event
mechan
action
antibodi
built
new
rbd
direct
antibodi
start
analysi
monomermonom
interfac
interact
observ
antibodi
crystal
complex
rbd
superimpos
spike
rbd
complex
compar
monomermonom
interfac
interact
observ
model
antibodi
complex
rbd
superimpos
protein
complex
fig
highlight
cdr
residu
tab
replac
aim
increas
affin
versu
spike
rbd
residu
mutatedreplac
chosen
accord
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
spacerestraint
chemic
need
better
complement
spike
rbd
surfac
base
avail
rbd
structur
complex
aim
produc
someth
resembl
surfac
tab
propos
mutat
residu
tab
sure
allow
alreadi
observ
correspond
site
known
antibodi
accord
chotiakabat
rule
http
wwwbioinforgukabschothiahtml
residu
replac
directli
perform
newli
gener
model
host
interact
spike
rbd
similarli
complex
modifi
antibodi
interact
rbd
also
creat
cdr
mutat
residu
report
tab
furthermor
mutat
residu
within
cdr
interact
spike
rbd
residu
observ
fig
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
engin
fab
portion
thu
align
superimpos
fab
portion
crystal
igg
sequenc
chimer
antibodi
observ
supp
interact
energi
calcul
spike
rbd
domain
nativ
antibodi
fab
portion
give
neg
valu
tab
confirm
might
bind
interact
nativ
antibodi
fab
portion
spike
rbd
result
encourag
also
due
indirect
valid
obtain
get
similar
interact
energi
crystal
rbd
complex
spike
rbd
domain
crystal
complex
respect
tab
furthermor
strong
interact
term
interact
energi
calcul
foldx
analys
complex
assay
also
predict
spike
rbd
also
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
spike
rbd
modifi
antibodi
see
tab
suggest
engin
might
effici
nativ
bind
spike
rbd
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
indic
pipelin
allow
setup
molecular
framework
host
spike
protein
receptor
differ
antibodi
pdb
session
could
handl
differ
molecular
visual
molecular
framework
possibl
studi
predict
molecular
level
interact
differ
piec
framework
help
within
present
molecular
framework
highlight
set
possibl
effici
interact
crystal
antibodi
spike
rbd
rais
question
possibl
test
directli
cultur
cell
expos
viru
hope
patient
start
observ
also
propos
set
modif
cdr
residu
result
higher
specif
antibodi
express
test
cultur
cell
along
develop
antibodi
engin
model
session
import
paper
publish
anoth
revis
support
hypothesi
may
abl
bind
spike
protein
also
possibl
pose
propos
molecular
framework
recent
propos
spike
rbd
direct
fab
antibodi
molecular
framework
like
one
propos
also
help
studi
put
role
ace
inhibitor
perturb
interact
inde
recent
propos
patient
treat
ace
inhibitor
might
expos
infect
although
refseq
access
number
repres
main
target
ace
inhibitor
testi
isoform
somat
isoform
among
studi
isoform
share
ident
residu
uncertain
data
ace
inhibitor
possibl
greater
select
versu
effect
express
regul
avail
literatur
structur
comparison
observ
rmsd
crystal
nativ
coordin
coordin
lower
notabl
presenc
ace
inhibitor
captopril
enalaprilat
lisinopril
produc
rmsd
lower
atom
coordin
cite
crystal
structur
refer
nativ
convers
establish
slightli
higher
rmsd
observ
nativ
howev
also
admit
inhibitor
employ
dosag
would
target
effici
observ
versu
presenc
inhibitor
bind
caviti
abl
induc
import
conform
chang
might
favour
greater
affin
versu
spike
rbd
thu
mechan
patient
treat
ace
inhibitor
would
expos
would
reli
posit
feedback
induc
ace
inhibitor
express
nevertheless
evid
support
hypothesi
need
deepen
conclus
present
analysi
highlight
import
use
fold
recognit
tool
along
approach
drug
design
problem
accord
ration
protocol
similar
previous
report
like
one
present
inde
case
fold
recognit
tool
help
us
identifi
crystal
structur
sarscovspik
protein
similar
investig
furthermor
perform
structur
compar
analysi
allow
identifi
possibl
good
start
point
like
one
repres
alreadi
crystal
complex
spike
rbd
build
propos
antibodi
strategi
might
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
appli
also
futur
infect
research
involv
draw
new
antibodi
andor
develop
new
vaccin
ie
deal
futur
coronavirus
best
knowledg
report
spike
protein
trimer
model
first
model
describ
possibl
conform
chang
lead
reliabl
spike
protein
post
fusion
conform
propos
model
base
murin
cov
spike
protein
crystal
post
fusion
conform
help
understand
mechan
allow
viru
envelop
fusion
host
cell
plasma
membran
follow
interact
furthermor
provid
model
postfus
conform
accord
crystal
structur
spike
protein
prefus
conform
confirm
presenc
stabil
sort
channel
interfac
three
monom
could
repres
good
target
site
virtual
screen
chemicaldrug
librari
aim
identifi
small
moleculepeptid
high
affin
monom
similarli
propos
peptid
prevent
trimer
format
stabil
small
moleculepeptid
high
affin
trimer
aim
prevent
conform
chang
lead
fusion
viral
envelop
host
cell
plasma
membran
screen
drug
librari
would
help
identifi
alreadi
approv
drug
high
affin
spike
channel
might
immedi
test
bedsid
context
drugreposit
approach
notabl
provid
molecular
framework
investigatingdraw
new
antibodi
base
spacerestraint
need
would
use
setup
new
antibodi
base
avail
tissuespecif
immunoglobulin
structur
propos
special
antibodi
alreadi
optim
target
specif
cell
receptor
also
among
may
success
target
respiratori
tract
might
administ
even
aerosol
time
alreadi
preclin
level
administ
vaccin
base
administr
entir
spike
protein
administr
singl
spike
rbd
induc
product
specif
antibodi
might
sequenc
model
silico
concern
provid
molecular
network
help
quantifi
interact
rbd
also
case
differ
rbd
variant
newli
investig
antibodi
ielow
calcul
bind
energi
model
complex
higher
likelihood
success
investig
vaccinesantibodi
discov
antibodi
highest
affin
rbd
might
also
implement
diagnosi
kit
aim
earli
identif
sera
also
asymptomat
peopl
convers
new
diagnosi
kit
could
also
base
nativ
rbd
modifi
synthet
rbd
greater
affin
detect
human
antibodi
direct
spike
rbd
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
protein
determin
real
number
healthi
peopl
alreadi
expos
viru
popul
lack
knowledg
real
number
peopl
expos
viru
includ
asymptomat
peopl
peopl
mild
symptom
rescu
peopl
never
need
hospit
quarantin
import
data
still
miss
without
data
real
number
peopl
expos
viru
popul
come
back
normal
life
extrem
slower
detail
instruct
setup
shown
molecular
framework
provid
manuscript
nevertheless
also
provid
free
assist
academ
analys
upon
request
also
provid
dedic
technic
support
analys
request
privat
compani
browser
srl
spinoff
case
pleas
write
info
browserbioinfcom
clp
cc
